NCT01690169View on ClinicalTrials.gov

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 14, 2012

Primary Completion Date

December 11, 2012

Study Completion Date

December 11, 2012

Conditions
DiabetesDiabetes Mellitus, Type 2Healthy
Interventions
DRUG

NNC0113-0987

A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.

DRUG

placebo

A single dose of oral placebo administered.

Trial Locations (1)

NG11 6JS

Novo Nordisk Investigational Site, Nottingham

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY